Feng Qin, Li Xuemei, Peng Jinghua, Duan Xiaohua, Fu Qilin, Hu Yiyang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Institute of Liver Disease of Shanghai University of Traditional Chinese Medicine, Shanghai 201201, China.
Zhongguo Zhong Yao Za Zhi. 2012 Feb;37(4):505-8.
To study the effect of gypenosides on DMN-induced liver fibrosis in rats.
A rat liver fibrosis model was established by injecting DMN intraperitoneally. Four weeks later, model rats were randomly devided into three groups: the model group, the gypenosides treated group (200 mg x kg(-1)) and the colchicine treated group (0.1 mg x kg(-1)), with 10 specimens for each group. After a 2-week treatment, following parameters were observed: (1) last body weight, weight ratio between liver and spleen; (2) content of liver hydroxyproline (Hyp); (3) activity of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (gamma-GT), content of albumin (Alb) and total bilirubin( TBiL) in serum; (4) liver pathology (Sirius red staining and HE staining); (5) activity of liver superoxide dismutase (SOD), glutathione reduced (GSH), glutathione peroxidase (GSH-Px) and content of liver maleic dialdehyde (MDA).
There were classic liver cirrhosis pathological changes in model groups. Compared with the normal group, liver Hyp content, activity of serum ATL, AST, gamma-GT and content of serum TBiL, MDA of model groups significantly increased; content of serum Alb and liver GSH, activity of liver SOD and GSH-Px decreased significantly in model groups. In comparison with the model group, liver cirrhosis remarkable improved in the gypenosides group, content of liver Hyp reduced significantly (P < 0.01), which was equal to the colchicine group. Compared with the model group, liver function parameters improved markedly in the gypenosides group; liver SOD and GSH-Px activities significantly increased; MDA content reduced significantly (P < 0.05).
Gypenosides shows an effect in treating DMN-induced liver fibrosis in rats.
研究绞股蓝总皂苷对二甲基亚硝胺（DMN）诱导的大鼠肝纤维化的影响。
通过腹腔注射DMN建立大鼠肝纤维化模型。四周后，将模型大鼠随机分为三组：模型组、绞股蓝总皂苷治疗组（200mg·kg⁻¹）和秋水仙碱治疗组（0.1mg·kg⁻¹），每组10只。治疗2周后，观察以下指标：（1）末次体重、肝脾重量比；（2）肝脏羟脯氨酸（Hyp）含量；（3）血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、γ-谷氨酰转移酶（γ-GT）活性，血清白蛋白（Alb）含量和总胆红素（TBiL）含量；（4）肝脏病理（天狼星红染色和苏木精-伊红染色）；（5）肝脏超氧化物歧化酶（SOD）、还原型谷胱甘肽（GSH）、谷胱甘肽过氧化物酶（GSH-Px）活性及肝脏丙二醛（MDA）含量。
模型组出现典型的肝硬化病理改变。与正常组相比，模型组肝脏Hyp含量、血清ALT、AST、γ-GT活性及血清TBiL、MDA含量显著升高；模型组血清Alb含量、肝脏GSH含量、肝脏SOD和GSH-Px活性显著降低。与模型组相比，绞股蓝总皂苷组肝硬化明显改善，肝脏Hyp含量显著降低（P<0.01），与秋水仙碱组相当。与模型组相比，绞股蓝总皂苷组肝功能指标明显改善；肝脏SOD和GSH-Px活性显著升高；MDA含量显著降低（P<0.05）。
绞股蓝总皂苷对DMN诱导的大鼠肝纤维化具有治疗作用。
